You are currently viewing Large Study Finds: Diabetes Drug Mounjaro Lost More Weight Than Those on Ozempic

Large Study Finds: Diabetes Drug Mounjaro Lost More Weight Than Those on Ozempic

In a recent real-world study, adults who are overweight or obese and took the injectable medication Mounjaro experienced more significant weight loss compared to those using Ozempic, a similar drug. Initially prescribed for type 2 diabetes management, these drugs have gained popularity for their potential to aid in significant weight loss. Further in this blog, we’ll discuss the difference between these medications, the study, and the result findings of these two drugs that have been buzzing all over the internet. With this, we’ll also talk about which medication works best for you. Let’s get on to the topic!

The Difference Between the Weekly Injections

Mounjaro and Ozempic, alongside their weight loss companions, are weekly injections designed to alter eating habits and reduce appetite. They achieve this by mimicking specific hormones in the gut. However, there is a distinction between the two. Ozempic and Wegovy, for instance, solely mimic a hunger-regulating hormone known as glucagon-like peptide-1 (GLP-1). This hormone enhances the sensation of fullness and decreases blood sugar levels, aiding in weight loss.

On the other hand, Mounjaro and Zepbound work by imitating two essential hormones in the gut: GLP-1 and GIP. This dual approach is designed to have a more substantial impact on controlling appetite and blood sugar levels. Some experts believe that this dual action could result in more significant weight loss compared to medications that target only GLP-1.

The Study and Real-World Implications

The latest study, although not yet peer-reviewed or published in a professional journal, provides valuable insights into the potential of tirzepatide for weight loss. This aligns with what doctors have noticed in their patients with diabetes, suggesting tirzepatide’s potency. However, there’s a scarcity of head-to-head comparisons between tirzepatide and other drugs, particularly in non-diabetic individuals. While such a study is underway, results are not expected for over a year. 

Dr. Patricia Rodriguez, the lead author of the study and a senior applied scientist at Truveta Research, highlights the significance of these findings, especially considering that over 70% of American adults struggle with weight issues. There’s a vast potential for these medications, but there’s a lack of such information.

It’s important to note that the study was not funded by the manufacturers of either tirzepatide or Wegovy. Instead, it was initiated by a data analytics company owned by 30 US healthcare systems named Truveta. Truveta combines anonymous patient records from these hospitals to conduct research. Both Eli Lilly and Novo Nordisk, the manufacturers of Ozempic and Wegovy, respectively, have stated that they do not endorse the off-label use of their medicines. They were not involved in this study. Additionally, the study does not take into account that Ozempic is typically administered at slightly lower doses compared to Wegovy, its counterpart for weight loss.

Study Results on Mounjaro and Ozempic

Truveta Research studied the health records of about 18,000 adults who were overweight or obese and began using Mounjaro or Ozempic from May 2022 to September 2023. Almost 52% of these patients had Type 2 diabetes. Researchers discovered that individuals taking Mounjaro were three times more likely to shed 15% of their body weight compared to those using Ozempic. Furthermore, those on Mounjaro had a 2.6 times higher chance of attaining a 10% weight loss and were 1.8 times more likely to lose 5% of their weight.

According to Truveta Research, people using Mounjaro experienced ‘significantly greater weight loss’ compared to those using Ozempic at specific times. After three months, Mounjaro users lost 5.9% of their weight, while Ozempic users lost 3.6%. By six months, Mounjaro users had lost 10.1% of their weight, compared to 5.9% for Ozempic users. At the one-year mark, Mounjaro users had lost 15.2% of their weight, while Ozempic users had lost 7.9%.

Truveta Research also discovered that people who don’t have type 2 diabetes lost more weight than those with the condition. However, both Mounjaro and Ozempic showed similar effectiveness in both populations. The rates of gastrointestinal events (stomach-related and other possible side effects) were also similar in patients taking these injectable medications.

The Best Medication Is the One That Works for You

When it comes to weight loss, the best medication is the one that suits you best. Everyone is different, and what works for one person may not work for another. Research often confirms what we see in clinical trials: people respond differently to weight loss drugs. According to the National Institutes of Health, more than 2 in 5 adults have obesity, and about 1 in 11 have severe obesity. That’s a significant number of people who could benefit from effective weight loss medications.

For example, some patients may not tolerate one form of a GLP-1 medication like Ozempic or Mounjaro but may do well with another. Both GLP-1 medications have proven beneficial not only for weight loss but also for managing diabetes and providing cardiovascular benefits. So, it’s crucial to work with your healthcare provider to find the right medication for you. What works for one person may not work for another, so it’s essential to find the right fit for your body and your health goals. The best medication is the one that works for you.

Future Directions and Clinical Trials

In an exciting development, Eli Lilly is currently conducting a clinical trial comparing Zepbound and Wegovy in obese or overweight patients. However, we’ll have to wait until 2025 for the results. A representative from Truveta Research shared that they’ve been able to compare the effectiveness of these two important medications for weight loss before the randomized clinical trials are completed. This comparison could provide valuable insights into the future of obesity treatment.

Final Conclusion

The recent real-world study comparing Mounjaro and Ozempic for weight loss has provided valuable insights. The study’s findings suggest that Mounjaro may lead to more significant weight loss compared to Ozempic, especially in individuals without type 2 diabetes. These medications, along with others like Zepbound and Wegovy, offer hope for those struggling with obesity.

It’s important to note that the best medication for weight loss is the one that works best for you. Everyone’s body responds differently, so it’s essential to work closely with your healthcare provider to find the right fit. As research continues and clinical trials progress, we can look forward to more advancements in obesity treatment. In the future, as we await the results of ongoing clinical trials, it’s exciting to see how medications like Zepbound and Wegovy may further impact obesity treatment. These studies could pave the way for new options and approaches to help individuals achieve their weight loss goals.


[Note: Buy Mounjaro online Canada at the most cost-effective prices and get it delivered to your doorsteps in the USA.]

Leave a Reply